<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2017-06-23" updated="2019-12-02">
  <drugbank-id primary="true">DB13518</drugbank-id>
  <name>Alginic acid</name>
  <description>Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961]. Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693]. It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46]. Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961].</description>
  <cas-number>9005-32-7</cas-number>
  <unii>8C3Z4148WZ</unii>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A27141</ref-id>
        <pubmed-id>1551350</pubmed-id>
        <citation>Castell DO, Dalton CB, Becker D, Sinclair J, Castell JA: Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid. Dig Dis Sci. 1992 Apr;37(4):589-93.</citation>
      </article>
      <article>
        <ref-id>A27142</ref-id>
        <pubmed-id>231639</pubmed-id>
        <citation>Malmud LS, Charkes ND, Littlefield J, Reilley J, Stern H, Rosenberg R, Fisher RS: The mode of action alginic acid compound in the reduction of gastroesophageal reflux. J Nucl Med. 1979 Oct;20(10):1023-8.</citation>
      </article>
      <article>
        <ref-id>A32960</ref-id>
        <pubmed-id>27671545</pubmed-id>
        <citation>Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, Umscheid CA, Lewis JD: Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12535.</citation>
      </article>
      <article>
        <ref-id>A32961</ref-id>
        <pubmed-id>10848650</pubmed-id>
        <citation>Mandel KG, Daggy BP, Brodie DA, Jacoby HI: Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000 Jun;14(6):669-90.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2693</ref-id>
        <title>FDA CFR - Code of Federal Regulations Title 21 Sec. 184.1011 Alginic acid</title>
        <url>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1011</url>
      </link>
      <link>
        <ref-id>L2695</ref-id>
        <title>ALGINIC ACID - National Library of Medicine HSDB Database - Toxnet</title>
        <url>https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2967</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F46</ref-id>
        <title>Gaviscon Summary of Product Characteristics</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/046/original/LicenseSPC_PA0979-015-001_21022014152038.pdf?1525723709</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for the management of gastric reflux, reflux oesophagitis, hiatus hernia, heartburn (including heartburn of pregnancy) and similar gastric distress [F46].</indication>
  <pharmacodynamics>Alginic acid reduces reflux via its floating, foaming, and viscous properties [A27142]. Alginic acid precipitates upon contact with gastric acid to create a mechanical barrier, or a "raft", that displaces the postprandial acid pocket [A32960]. The formation of a raft is thought to occur rapidly, often within a few seconds of dosing [A32961]. In clinical trials, alginic acid was effective in reducing the symptoms of gastroesophageal reflux disease (GERD) [A32960]. In healthy volunteers, alginic acid in combination with an antacid was effective in decreasing postprandial reflux in the upright position [A27141]. Alginic acid is able to bind to cations when ingested [L2695]. </pharmacodynamics>
  <mechanism-of-action>Once orally administered, alginic acid reacts with gastric acid to form a floating "raft" of alginic acid gel on the gastric acid pool. Alginate-based raft-forming formulations commonly contain sodium or bicarbonate; bicarbonate ions are converted to carbon dioxide in presence of gastric acid and get entrapped within the gel precipitate, converting it into a foam which floats on the surface of the gastric contents, much like a raft on water [A32961]. The "raft" has a near neutral pH due to carbon dioxide and floats on the stomach contents and potentially functions as a barrier to impede gastroesophageal reflux [A27141, F46]. In severe cases, the raft itself may be refluxed into the oesophagus in preference to the stomach contents and exert a demulcent effect [F46]. </mechanism-of-action>
  <toxicity>Probable oral lethal dose reported in humans is above 15 g/kg [L2695]. Ingestion of large quantities may result in abdominal distension, intestinal obstruction, nausea, vomiting, and difficulty swallowing. Aspiration or inhalation may lead to pneumonitis [L2695]. In the event of overdosage symptomatic treatment should be given [F46].</toxicity>
  <metabolism>This pharmacokinetic parameter is unlikely to apply for alginic acid. </metabolism>
  <absorption>The absorption into the systemic circulation from oral formulations of alginic acid is reported to be minimal, as the mode of action of alginic acid is physical [F46]. </absorption>
  <half-life>This pharmacokinetic parameter is unlikely to apply for alginic acid. </half-life>
  <protein-binding>This pharmacokinetic parameter is unlikely to apply for alginic acid. </protein-binding>
  <route-of-elimination>This pharmacokinetic parameter is unlikely to apply for alginic acid. </route-of-elimination>
  <volume-of-distribution>This pharmacokinetic parameter is unlikely to apply for alginic acid. </volume-of-distribution>
  <clearance>This pharmacokinetic parameter is unlikely to apply for alginic acid. </clearance>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002812</drugbank-id>
      <name>Sodium alginate</name>
      <unii>C269C4G2ZQ</unii>
      <cas-number>9005-38-3</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(Alginate)n</synonym>
    <synonym language="english" coder="">(Alginate)n+1</synonym>
    <synonym language="english" coder="">algin</synonym>
    <synonym language="english" coder="">alginate</synonym>
    <synonym language="english" coder="inn">Alginic acid</synonym>
    <synonym language="english" coder="">Norgine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Gastrocote Chewable Tab</name>
      <labeller>Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01941879</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Butterscotch Flavour Tablets</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02159813</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-15</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Extra Strength Butterscotch Flavoured Tablets</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230582</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-15</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Extra Strength Strawberry Fl.tabs</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02159805</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-15</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Extra Strength Tablets</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230581</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-15</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Heartburn Relief Liquid</name>
      <labeller>Sterling Winthrop Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02085720</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Heartburn Relief Tablets</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02142651</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Icy Mint Flavour Liq</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02159767</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-15</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Liquid - Fruit &amp; Mint Flavours</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02142643</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-15</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Tablets</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02159783</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Tablets - Butterscotch and Fr.fl.</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02142627</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gaviscon Tabs Extra Strength</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02142635</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Heartburn Relief</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231418</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-07-29</started-marketing-on>
      <ended-marketing-on>2006-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Heartburn Relief - Tab</name>
      <labeller>Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02219573</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-18</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Maalox Hrf Suspension</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238388</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-12-08</started-marketing-on>
      <ended-marketing-on>2009-06-29</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rafton Liquid - Fruit Flavour</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01992473</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-17</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rafton Tablets - Fruit Flavour</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01995081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral; Other</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tums Dual Action</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248628</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-01</started-marketing-on>
      <ended-marketing-on>2008-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ultraplast Alginate Styptic Gauze</name>
      <labeller>Wallace, Cameron and Company Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00206946</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-20</ended-marketing-on>
      <dosage-form>Dressing</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ultrastat</name>
      <labeller>Wallace, Cameron and Company Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00280704</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-20</ended-marketing-on>
      <dosage-form>Aerosol</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zinc and Algin Tab Nu Life</name>
      <labeller>Nu Life Nutrition Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00345415</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on>2000-03-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Ultraplast Alginate Styptic Gauze</name>
      <ingredients>Alginic acid + Calcium alginate + Domiphen</ingredients>
    </mixture>
    <mixture>
      <name>Gastrocote Chewable Tab</name>
      <ingredients>Alginic acid + Aluminum hydroxide + Magnesium trisilicate + Sodium bicarbonate</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Heartburn Relief Liquid</name>
      <ingredients>Alginic acid + Magnesium carbonate</ingredients>
    </mixture>
    <mixture>
      <name>Ultrastat</name>
      <ingredients>Alginic acid + Chlorhexidine</ingredients>
    </mixture>
    <mixture>
      <name>Rafton Tablets - Fruit Flavour</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Rafton Liquid - Fruit Flavour</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Tablets - Butterscotch and Fr.fl.</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Liquid - Fruit &amp; Mint Flavours</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Heartburn Relief Tablets</name>
      <ingredients>Alginic acid + Magnesium carbonate</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Tabs Extra Strength</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Zinc and Algin Tab Nu Life</name>
      <ingredients>Alginic acid + Zinc</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Icy Mint Flavour Liq</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Extra Strength Strawberry Fl.tabs</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Butterscotch Flavour Tablets</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Heartburn Relief - Tab</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Tablets</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Extra Strength Tablets</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Gaviscon Extra Strength Butterscotch Flavoured Tablets</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Heartburn Relief</name>
      <ingredients>Alginic acid + Aluminum hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Maalox Hrf Suspension</name>
      <ingredients>Alginic acid + Calcium carbonate + Magnesium carbonate</ingredients>
    </mixture>
    <mixture>
      <name>Tums Dual Action</name>
      <ingredients>Alginic acid + Calcium carbonate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Acids, Aldehydic</category>
      <mesh-id>D000145</mesh-id>
    </category>
    <category>
      <category>Alginates</category>
      <mesh-id>D000464</mesh-id>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Drugs for Acid Related Disorders</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glucuronates</category>
      <mesh-id>D005965</mesh-id>
    </category>
    <category>
      <category>Hexuronic Acids</category>
      <mesh-id>D006603</mesh-id>
    </category>
    <category>
      <category>Hydroxy Acids</category>
      <mesh-id>D006880</mesh-id>
    </category>
    <category>
      <category>Polysaccharides</category>
      <mesh-id>D011134</mesh-id>
    </category>
    <category>
      <category>Sugar Acids</category>
      <mesh-id>D013400</mesh-id>
    </category>
    <category>
      <category>Uronic Acids</category>
      <mesh-id>D014574</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral; Other</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Dressing</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Aerosol</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A02BX13">
      <level code="A02BX">Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)</level>
      <level code="A02B">DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)</level>
      <level code="A02">DRUGS FOR ACID RELATED DISORDERS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>418.2275</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>418.042999128</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OC1C(O)C(OC2C(O)C(O)C(OP)OC2C(O)=O)OC(C1P)C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H20O12P2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H20O12P2/c13-1-3(15)12(24-26)22-6(9(17)18)5(1)21-11-4(16)2(14)8(25)7(23-11)10(19)20/h1-8,11-16H,25-26H2,(H,17,18)(H,19,20)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>FHVDTGUDJYJELY-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6032</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9763</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>17548</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>131704328</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347829302</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C01768</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02324</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alginic_acid</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>